Rare Cancer
-
What Is Tumor Mutational Burden?
The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.
by Anna Azvolinsky
-
Survivor Profile
An Unlikely Pivot
Medha Deoras-Sutliff's experience with breast cancer fueled her interest in advocacy for breast cancer patients and, more recently, her support for research on rare cancers.
by Lindsey Konkel
-
Survivor Profile
Sharing Her Strength
Diagnosed with two cancers prior to turning 40, Rebecca Esparza uses her voice to advocate for policy changes to help people affected by cancer.
by Lindsey Konkel
-
Advocacy in Action
Leaving a Legacy
Two mothers, each with a son who died of brain cancer, worked together to increase awareness and acceptance of tumor tissue donation.
by Esther Landhuis
-
A Unified Strategy
A couple who lost their daughter to brain cancer builds a charity that connects parents, hospitals and researchers with data.
by Marci A. Landsmann
-
Finding More Targets for CAR-T Cells
CAR-T cell therapy has successfully treated some patients with leukemia and lymphoma. Researchers are looking to expand the range of cancers that will respond to the therapy.
by Kendall K. Morgan
-
Survivor Profile
Still in the Game
ESPN reporter Holly Rowe worked through melanoma treatment.
by Lindsey Konkel
-
More Options for Rare Cancers
Precision medicine and immunotherapy offer opportunities for new treatments and clinical trials to patients who previously had few, if any, options.
by Kendall K. Morgan
-
An Uncommon Partnership
Through the Angiosarcoma Project, researchers are partnering with patients to learn about a rare cancer.
by Ashley P. Taylor
-
Learning to Share
At first, I wanted to hide my cancer diagnosis. My son showed me what a mistake that was.
by Lenn Robbins
